Overview

Opiate Suicide Study in Patients With Major Depression

Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
To explore whether intravenous ketamine followed by buprenorphine produces more rapid and sustained anti-suicidal effects than ketamine followed by placebo, investigators will conduct a single study that will take approximately 2.5 years to complete. 60 subjects (60 infusions) or approximately 24 infusions per year.
Phase:
Phase 3
Details
Lead Sponsor:
Stanford University
Treatments:
Buprenorphine
Ketamine